AMENDMENTS TO THE CLAIMS

1. *(Currently Amended)* A system for treating an individual experiencing a chronic physiologic condition that is characterized by abnormal levels of cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, the system comprising a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and ~~means~~ tubing for circulating the blood of the individual through the material, the tubing having a wall impregnated with the material.

2. *(Currently Amended)* A system according to claim 1

further including ~~means for administering~~ a source of an agent selected to be administered to the individual ~~selected~~ to treat the chronic physiologic condition.

3. *(Currently Amended)* A system according to claim 1

wherein the ~~means for circulating~~ tubing includes an intravenous catheter.

4. *(Currently Amended)* A system according to claim 1

wherein the ~~means for circulating~~ tubing includes an indwelling catheter.

5 -7. *(Canceled)*

8. *(Currently Amended)* A system according to claim 1

wherein the ~~means for circulating and the material are~~ tubing is sized to be carried with the individual during ambulation.

9. *(original)* A system according to claim 1

wherein the material is characterized by a Biocompatibility Index of not greater than 14.

10. *(original)* A system according to claim 9

wherein the Biocompatibility Index is not greater than 7.

11. *(original)* A system according to claim 1

wherein the material comprises a polymeric material.

12. *(original)* A system according to claim 11

wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

13. *(original)* A system according to claim 11

wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

14. *(original)* A system according to claim 11

wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

15. *(original)* A system according to claim 11

wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ-solvents.

16 – 61 *(cancelled)*.

62. *(Currently Amended)* A system for treating an individual experiencing trauma before onset of septic shock comprising a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and ~~means~~ tubing for circulating the blood of the individual through the material, the tubing having a wall impregnated with the material.

63. *(Currently Amended)* A system according to claim 62

further including ~~means for administering~~ a source of an agent selected to be administered to the individual ~~selected~~ to treat trauma.

64. *(Currently Amended)* A system according to claim 62

wherein the ~~means for circulating~~ tubing includes an intravenous catheter.

65. *(Currently Amended)* A system according to claim 62

wherein the ~~means for circulating~~ tubing includes an indwelling catheter.

66 - 68. *(Canceled)*

69. *(Currently Amended)* A system according to claim 68

wherein the ~~means for circulating and the material are~~ tubing is sized to be carried with the individual during ambulation.

70. *(original)* A system according to claim 62

wherein the material is characterized by a Biocompatibility Index of not greater than 14.

71. *(original)* A system according to claim 70

wherein the Biocompatibility Index is not greater than 7.

72. *(original)* A system according to claim 62

wherein the material comprises a polymeric material.

73. *(original)* A system according to claim 72

wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

74. *(original)* A system according to claim 72

wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

75. *(original)* A system according to claim 72

wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

76. *(original)* A system according to claim 72

wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ-solvents.

77 – 92 (*cancelled*).